Compare Cassava Sciences Inc (FLNA) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Sibanye Stillwater Ltd — how do they compare? Cassava Sciences Inc trades at $1.08 (market cap $53.14M), while Sibanye Stillwater Ltd trades at $8.09 (market cap $5.93B). The key difference: Sibanye Stillwater Ltd is far larger — about 111.6× Cassava Sciences Inc's market cap, and Sibanye Stillwater Ltd pays a 3.64% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | SBSW | |
|---|---|---|
Market Cap | $53.14M | $5.93B |
Sector | Health | Basic Materials |
52-Week High | $4.64 | $21.12 |
52-Week Low | $1.09 | $7.27 |
Enterprise Value | -$33.43M | $7.56B |
Dividend Yield | — | 3.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Sibanye Stillwater (SBSW) trades at $8.12, down 5.25% today, reflecting ongoing challenges despite a low P/E of 4.76 and P/S of 0.77. The stock shows bearish technical signals with key support at $8, while fundamentals reveal negative net income margins and ROE. Recent news highlights operational improvements, including a surge in EBITDA and management's debt reduction targets, yet earnings misses in recent quarters underscore persistent profitability issues.
The outlook is mixed: deep valuation discounts and analyst consensus targets near $14.25 suggest upside potential, but risks from volatile commodity prices, high debt, and inconsistent earnings warrant caution. Investors should weigh the turnaround narrative against fundamental weaknesses before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
